Kiniksa Pharmaceuticals International
KNSA
77.96
+0.87
+1.13%
Kiniksa Pharmaceuticals International
US · KNSA
#1938 by market cap
Listed 2018
77.96
+0.87
+1.13%
Live - 5344 symbols - heartbeat 508s ago
· 2026-10-07 19:54
After-hours
78.50
+0.69%
- Market cap
- 6.08B
- P/E (TTM)i
- 78.75
- P/Bi
- 9.30
- EPSi
- 0.75
- Div yieldi
- 0.00%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on KNSA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.0 percentage points.
Institutional ownership
- Held by institutions
- 61.53% -0.96pp
- Institutions
- 326 +5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund41.01%
Hedge Fund14.86%
Individual/Insider4.35%
Public Company2.58%
Private Company1.47%
VC/PE Fund0.69%
Government Pension Fund0.63%
Insurance Company0.13%
Bank/Investment Bank0.11%
Other34.18%
Top holders as of 2026-06-30
FMR
8.93% · 6.97M sh
Rubric Capital Management LP
5.13% · 4.00M sh
Baker Bros. Advisors LP
3.63% · 2.83M sh
BlackRock
3.51% · 2.74M sh
Tang Capital Management, LLC
2.90% · 2.26M sh
Vanguard Portfolio Management, LLC
2.45% · 1.91M sh
Sanjiv Patel
2.35% · 1.83M sh
Vanguard Capital Management, LLC
1.84% · 1.43M sh
Robert Desnick
1.63% · 1.27M sh
Morgan Stanley
1.28% · 1.00M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 40 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| Sanjiv Patel | Chairperson & CEO | 2.35% |
| John Paolini | Senior VP & Chief Medical Officer | 0.09% |
| Michael Megna | Chief Accounting Officer & Group VP of Finance | 0.04% |
| Eben Tessari | Senior Vice President | 0.03% |
| Richard Levy | Independent Director | 0.03% |
| Mark Ragosa | Senior Vice President | 0.03% |
| Ross Moat | Chief Commercial Officer | 0.02% |
| Tracey McCain | Independent Director | 0.02% |
| Kimberly Popovits | Independent Director | 0.02% |
| Thomas Malley | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Derivative Exercise and Sale | -10,131 | $79.28–80.30 |
| 2026-09-02 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Intent to Sell (Form 144) | -4,600 | $80.30 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Sale | -15,144 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +30,050 | -- |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +120,150 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Retained | +16,174 | -- |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Derivative Exercise and Sale | -4,029 | $79.28 |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +6,700 | -- |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +26,750 | $79.28 |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Derivative Exercise and Retained | +4,299 | -- |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Derivative Exercise and Sale | -4,404 | $79.28 |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Other Derivative Acquisition | +7,800 | -- |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Other Derivative Acquisition | +31,150 | $79.28 |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Derivative Exercise and Retained | +4,700 | -- |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Other Derivative Acquisition | +3,650 | -- |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Other Derivative Acquisition | +14,600 | $79.28 |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Derivative Exercise and Retained | +1,365 | -- |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Derivative Exercise and Sale | -4,007 | $79.28 |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Other Derivative Acquisition | +9,250 | -- |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Other Derivative Acquisition | +36,950 | $79.28 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.